News for Celldex Therapeutics, Inc. (CLDX)

Morgan Stanley backs Celldex Therapeutics for growth with barzolvolimab's market-leading potential in chronic urticaria. Read more here.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

Celldex Therapeutics Inc (CLDX), a clinical-stage biotechnology company, announced on March 4, 2025, that its management will participate in fireside chats at t

HAMPTON, N.J., March 04, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (CLDX) announced today that management will participate in fireside chats at two

Summary Celldex Therapeutics Inc (CLDX) announced on March 1, 2025, promising results from its Phase 2 studies of barzolvolimab, a humanized monoclonal antibody

- Greatly improved patient quality of life and reduced disease impact in patients with CSU and CIndU -- 82% of CSU patients reported that symptoms no longer had

Strengths: Innovative immunotherapy technologies and a robust pipeline targeting severe diseases.Weaknesses: High research and development costs with no produc

Celldex (CLDX) delivered earnings and revenue surprises of 5.33% and 24.19%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Celldex Therapeutics Inc (CLDX) announced its financial results for the fourth quarter and full year ending December 31, 2024, alongside a corporate update on F

Revenue: $1.2 million for Q4 2024, slightly surpassing the estimated $1.12 million.Earnings Per Share (EPS): Reported at ($0.71) for Q4 2024, aligning with the

Enrollment ongoing in Phase 3 barzolvolimab CSU studies; Phase 3 program in CIndU under developmentPhase 2 barzolvolimab EOE study fully accrued; Phase 2 study

**media[552836]**

U.S. stock futures were higher this morning, with the Dow futures gaining around 50 points on Tuesday. Shares of Baidu, Inc. BIDU fell in today's pre-market tr...

On December 31, 2024, Kynam Capital Management, LP (Trades, Portfolio) executed a significant transaction by acquiring an additional 2,677,075 shares of Syndax

On December 31, 2024, Kynam Capital Management, LP (Trades, Portfolio) made a significant move by acquiring an additional 3,257,863 shares of enGene Holdings In

On December 31, 2024, Kynam Capital Management, LP (Trades, Portfolio) executed a significant transaction involving the reduction of its holdings in Dynavax Tec

Significant Transaction in Celldex Therapeutics Inc On December 31, 2024, Kynam Capital Management, LP (Trades, Portfolio) executed a notable transaction by inc

On December 31, 2024, FMR LLC (Trades, Portfolio), a prominent investment firm, executed a significant transaction involving Celldex Therapeutics Inc (CLDX). Th

Celldex has a strong cash position with a runway of 13-14 quarters, bolstered by a $424 million secondary offering in March 2024. Learn more on CLDX stock here.